Cytophage Develops Freeze-Dried Phage Tablets For Poultry

FULL DISCLOSURE: This is sponsored content for Cytophage Technologies.

Cytophage Technologies (TSXV: CYTO) has announced the launch of a simplified application option for its bacteriophages that it believes will set itself apart within the phage industry globally.

The company has developed a lyophilized phage tablet intended to treat multiple types of bacteria, including E. coli and Salmonella, throughout the lifecycle of poultry. The use of lyophilized phage tablets is providing an alternative to the liquid form that is presently used in the industry, which most often requires a cold chain.

”The importance of eliminating the need for a cold chain cannot be overstated. Offering phages in lyophilized form represents a competitive advantage over other phage producers who have only liquid products that require refrigeration. Our innovative manufacturing increases our products’ heat tolerance and shelf-life,” commented Dr Steven Theriault.

READ: Cytophage Enters Letter Of Intent With Major Singapore-Based Agrifood Company

The tablets are freeze dried and stabilized, which enable Cytophage’s phage products to be more easily used in hot climates such as Southeast Asia. The tablets are ready to use, dose controlled, and dissolve in water for application.

Development of the tablet is said to be a direct response to Cytophage working with the poultry industry on phage products that assist in reducing the use of broad-spectrum antibiotics, and replacing those antibiotics with target phages. The firm intends to leverage the new product format across its existing and pending product lines globally.

Cytophage Technologies last traded at $0.35 on the TSX Venture.


FULL DISCLOSURE: Cytophage Technologies is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of Cytophage Technologies. The author has been compensated to cover Cytophage Technologies on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

New Found Gold: The Strategic Maritime Resources Purchase

Amex Exploration: Revised Perron PEA Has INSANE Economics

Aris Mining: The Multi Billion Dollar Soto Norte PFS

Recommended

Canadian Copper Secures $8 Million Lead Order From Ocean Partners As Part Of Larger Funding Round

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Related News

Cytophage Adds 30-Year Biotech Exec To Its Board

Cytophage Technologies (TSXV: CYTO) has added bench strength to its board of directors this morning,...
Monday, May 27, 2024, 09:09:36 AM

McDonald’s E.coli Crisis: This Canadian Biotech May Have The Solution | Cytophage with Steven Theriault

In this interview, Dr. Steven Theriault, CEO & Chief Science Officer of Cytophage Technologies (TSXV:...
Saturday, November 16, 2024, 09:13:00 AM

Cytophage Reports Early Success In Single Subject Clinical Trial

Cytophage Technologies (TSXV: CYTO) has seen early success in a recently completed human trial conducted...
Tuesday, April 2, 2024, 09:05:42 AM

Cytophage Sees Its Bacteriophages Used As Treatment In Canada Under Single Subject Clinical Trial

For the first time in Canadian history, bacteriophage therapy is slated to be utilized to...
Friday, March 1, 2024, 10:14:56 AM

Cytophage Enters Partnership To Launch Phage Clinical Treatment Program In Manitoba

Cytophage Technologies (TSXV: CYTO) announced a landmark agreement this morning that will see the establishment...
Thursday, December 12, 2024, 05:14:00 PM